The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...